Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2019 | Photodynamic Therapy | Retinal Disorders

Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence

Authors: Wookyung Park, Mirinae Kim, Rae Young Kim, Young-Hoon Park

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2019

Abstract

Purpose

To compare the effects of full-dose, half-dose, and half-dose-half-fluence photodynamic therapy (PDT) in central serous chorioretinopathy (CSC).

Methods

This retrospective study enrolled patients with CSC who received full-dose (verteporfin 6 mg/m²), half-dose (verteporfin 3 mg/m²), and half-dose-half-fluence (verteporfin 3 mg/m² and light energy reduced to 25 J/cm²) PDT. We measured visual acuity, subfoveal choroidal thickness (SFCT), subretinal fluid (SRF) thickness, and choroidal vascularity index (CVI) before and 3 months after PDT.

Results

Forty-three eyes (42 patients) were analyzed. Full-dose and half-dose groups showed improved vision (P = 0.023, 0.004, respectively), but half-dose-half-power group was not significantly improved (P = 0.254). SFCT in all three groups were significantly decreased (P = 0.005, 0.004, 0.002, respectively). SRF thicknesses in full-dose and half-dose groups showed significant decreases (P = 0.005, < 0.001, respectively). Half-dose-half-fluence group demonstrated the decrease but it was not statistically significant (P = 0.084). CVI were decreased in full-dose and half-dose groups (all P = 0.005). However, in the half-dose-half-fluence group, CVI was increased (P = 0.003).

Conclusion

Full-dose and half-dose PDT were both effective in CSC treatment. Half-dose PDT can be considered to reduce complications. The effect of half-dose-half-fluence PDT was less clear than the other two protocols.

Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87(12):1453–1458CrossRefPubMedPubMedCentral

Taban M, Boyer DS, Thomas EL, Taban M (2004) Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 137(6):1073–1080. https://doi.org/10.1016/j.ajo.2004.01.043 CrossRefPubMed

Lim JI, Glassman AR, Aiello LP, Chakravarthy U, Flaxel CJ, Spaide RF, Macula Society Csc Collaborative Study Group R, Education C, Website C (2014) Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 121(5):1073–1078. https://doi.org/10.1016/j.ophtha.2013.11.040 CrossRefPubMed

Group ToA-rMDWPTTS (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Arch Ophthalmol 117(10):1329–1345CrossRef

Bressler NM, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study G (2001) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch Ophthalmol 119(2):198–207

Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58(2):103–126. https://doi.org/10.1016/j.survophthal.2012.07.004 CrossRefPubMedPubMedCentral

Erikitola OC, Crosby-Nwaobi R, Lotery AJ, Sivaprasad S (2014) Photodynamic therapy for central serous chorioretinopathy. Eye (Lond) 28(8):944–957. https://doi.org/10.1038/eye.2014.134 CrossRef

Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelen ME (2016) A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 170:91–99. https://doi.org/10.1016/j.ajo.2016.07.026 CrossRefPubMed

Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS (2006) Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 90(7):869–874. https://doi.org/10.1136/bjo.2006.090282 CrossRefPubMedPubMedCentral

10.

Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S (2013) Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina 33(2):316–323. https://doi.org/10.1097/IAE.0b013e318280769c CrossRefPubMed

11.

Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D (1994) Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 112(8):1057–1062CrossRefPubMed

12.

Prunte C, Flammer J (1996) Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 121(1):26–34CrossRefPubMed

13.

Hua R, Liu L, Li C, Chen L (2014) Evaluation of the effects of photodynamic therapy on chronic central serous chorioretinopathy based on the mean choroidal thickness and the lumen area of abnormal choroidal vessels. Photodiagn Photodyn Ther 11(4):519–525. https://doi.org/10.1016/j.pdpdt.2014.07.005 CrossRef

14.

Agrawal R, Chhablani J, Tan KA, Shah S, Sarvaiya C, Banker A (2016) Choroidal vascularity index in central serous chorioretinopathy. Retina 36(9):1646–1651. https://doi.org/10.1097/IAE.0000000000001040 CrossRefPubMed

15.

Izumi T, Koizumi H, Maruko I, Takahashi Y, Sonoda S, Sakamoto T, Iida T (2017) Structural analyses of choroid after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy. Br J Ophthalmol 101(4):433–437. https://doi.org/10.1136/bjophthalmol-2016-308921 CrossRefPubMed

16.

Shinojima A, Kawamura A, Mori R, Fujita K, Yuzawa M (2011) Detection of morphologic alterations by spectral-domain optical coherence tomography before and after half-dose verteporfin photodynamic therapy in chronic central serous chorioretinopathy. Retina 31(9):1912–1920. https://doi.org/10.1097/IAE.0b013e3182252aa8 CrossRefPubMed

17.

Maruko I (2012) Evaluation of the choroid in central serous chorioretinopathy. Nippon Ganka Gakkai Zasshi 116(11):1062–1079PubMed

18.

Tan R, Agrawal R, Taduru S, Gupta A, Vupparaboina K, Chhablani J (2018) Choroidal vascularity index in retinitis pigmentosa: an OCT study. Ophthalmic Surg Lasers Imaging Retina 49(3):191–197. https://doi.org/10.3928/23258160-20180221-07 CrossRefPubMed

19.

Kinoshita T, Mitamura Y, Mori T, Akaiwa K, Semba K, Egawa M, Mori J, Sonoda S, Sakamoto T (2016) Changes in choroidal structures in eyes with chronic central serous chorioretinopathy after half-dose photodynamic therapy. PLoS One 11(9):e0163104. https://doi.org/10.1371/journal.pone.0163104 CrossRefPubMedPubMedCentral

20.

Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM (2003) Photodynamic therapy for chronic central serous chorioretinopathy. Retina 23(6):752–763CrossRefPubMed

21.

Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM Jr, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23(3):288–298CrossRefPubMed

22.

Nicolo M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153(3):474–480 e471. https://doi.org/10.1016/j.ajo.2011.08.015 CrossRefPubMed

23.

Nicolo M, Eandi CM, Alovisi C, Grignolo FM, Traverso CE, Musetti D, Cardillo Piccolino F (2014) Half-fluence versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 157(5):1033–1037. https://doi.org/10.1016/j.ajo.2014.01.022 CrossRefPubMed

24.

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 122(3):555–561. https://doi.org/10.1016/j.ophtha.2014.09.034 CrossRefPubMed

25.

Chan WM, Lai TY, Lai RY, Liu DT, Lam DS (2008) Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 115(10):1756–1765. https://doi.org/10.1016/j.ophtha.2008.04.014 CrossRefPubMed

Title: Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence
Authors: Wookyung Park
Mirinae Kim
Rae Young Kim
Young-Hoon Park
Publication date: 01-10-2019
Publisher: Springer Berlin Heidelberg
Keyword: Photodynamic Therapy
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2019
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-019-04426-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Comparing effects of photodynamic therapy in central serous chorioretinopathy: full-dose versus half-dose versus half-dose-half-fluence

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2019

Cytokine production in thyroid eye disease: in vitro effects of dexamethasone and IL-6 blockade with tocilizumab

Full-field electroretinogram behavior in Vogt-Koyanagi-Harada disease: a 24-month longitudinal study in patients from acute onset evaluated with multimodal analysis

Vitreo-macular interface disorders in retinitis pigmentosa

Analysis of retinal nerve fiber layer thickness in anisometropic amblyopia via optic coherence tomography

Influence of holding weights of different magnitudes on intraocular pressure and anterior eye biometrics

Results of lamellar macular hole-associated epiretinal proliferation embedding technique for the treatment of degenerative lamellar macular hole